Tumor markers may help identify HER2+ breast cancer patients for less intensive chemotherapy

A study by the ECOG-ACRIN Cancer Research Group found that tumor markers, particularly HER2DX, can help identify HER2+ breast cancer patients who may respond to less intensive chemotherapy, with a higher pCR rate in those with high HER2DX scores.

Why it matters. This could lead to more personalized treatment approaches, reducing unnecessary chemotherapy and improving outcomes for certain patients.